Physician profile
Jonathan Doolan
NPI 1154057198
$571.98
in general payments reported to CMS, 2019-2025
10 companies · $263 in 2025
The $263 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $17.17 · 2023: $17.78 · 2024: $274 · 2025: $263.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $555.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $554.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $138.31 | 2022-2025 | Mounjaro, Zepbound |
| Pfizer INC. | $124.67 | 2024-2025 | |
| Amgen INC. | $65.43 | 2025 | Evenity, Krystexxa, Prolia |
| Astrazeneca Pharmaceuticals Lp | $59.60 | 2025 | Airsupra |
| Novo Nordisk INC | $41.19 | 2024 | Rybelsus, Ozempic |
| Dexcom, INC. | $36.85 | 2024 | Dexcom G6 Transmitter |
| Supernus Pharmaceuticals, INC. | $31.16 | 2024 | Qelbree |
| Exact Sciences Corporation | $30.49 | 2024-2025 | Cologuard Collection Kit |
| Boehringer Ingelheim Pharmaceuticals, INC. | $23.28 | 2025 | Jardiance |
| Sanofi-Aventis U.S. LLC | $21.00 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jonathan Doolan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.